$STIM News

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics Collaborates With ANT Neuro To Expand NeuroStar Advanced Therapy System

Neuronetics, Inc. Q1 2026 Earnings Call Summary

Neuronetics (STIM) Q1 2026 Earnings Transcript

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics Inc (NASDAQ:STIM) Posts Narrower Loss in Q1 2026, Pre-Market Rises Despite Revenue Miss

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Full Transcript: Neuronetics Q1 2026 Earnings Call

Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$166.000M vs $162.467M Est

Neuronetics Q1 EPS $(0.16) Beats $(0.17) Estimate, Sales $34.454M Beat $34.183M Estimate

How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price Target

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Form4 Filing Shows Jorey Chernett Bought 200K Shares At An Average Price Of $1.54/Share

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

How The Neuronetics (STIM) Investment Story Is Reset As Analysts Rework Valuation Assumptions

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

Neuronetics Comments on Letter from Pointillist Family Office